EMPRISE EMPAGLIFLOZIN REAL-WORLD EFFECTIVENESS Trademark

Trademark Overview


On Friday, September 28, 2018, a trademark application was filed for EMPRISE EMPAGLIFLOZIN REAL-WORLD EFFECTIVENESS with the United States Patent and Trademark Office. The USPTO has given the EMPRISE EMPAGLIFLOZIN REAL-WORLD EFFECTIVENESS trademark a serial number of 79249526. The federal status of this trademark filing is REGISTERED as of Tuesday, July 2, 2019. This trademark is owned by Boehringer Ingelheim International GmbH. The EMPRISE EMPAGLIFLOZIN REAL-WORLD EFFECTIVENESS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Medical and scientific research in the field of diabetes, cardiovascular diseases and chronic kidney disease; Providing medical and scientific research information in the field of diabetes, cardiovascular diseases and chronic kidney disease
emprise empagliflozin real-world effectiveness

General Information


Serial Number79249526
Word MarkEMPRISE EMPAGLIFLOZIN REAL-WORLD EFFECTIVENESS
Filing DateFriday, September 28, 2018
Status700 - REGISTERED
Status DateTuesday, July 2, 2019
Registration Number5791084
Registration DateTuesday, July 2, 2019
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, April 16, 2019

Trademark Statements


Description of MarkThe mark consists of the wording "EMPRISE" in black font. Below this is the wording "EMPAGLIFLOZIN REAL-WORLD EFFECTIVENESS" in blue. To the right of the wording is a red heart with magnifying glass covering the upper right portion of the heart. The magnifying glass is white and the lens of the magnifying glass is purple. Inside the lens is a stylized outline of a globe that transitions from white to purple from right to left. The color white appearing elsewhere in the mark is for background purposes only and is not claimed as a feature of the mark.
Pseudo MarkEMPRISE EMPAGLIFLOZIN REAL WORLD EFFECTIVENESS
Indication of Colors claimedThe color(s) black, white, blue, purple, and red is/are claimed as a feature of the mark.
NOT AVAILABLE"EMPAGLIFLOZIN REAL-WORLD EFFECTIVENESS"
Goods and ServicesMedical and scientific research in the field of diabetes, cardiovascular diseases and chronic kidney disease; Providing medical and scientific research information in the field of diabetes, cardiovascular diseases and chronic kidney disease

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, January 16, 2019
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBoehringer Ingelheim International GmbH
Party Type30 - Original Registrant
Legal Entity Type27 - NOT AVAILABLE
AddressDE

Party NameBoehringer Ingelheim International GmbH
Party Type20 - Owner at Publication
Legal Entity Type27 - NOT AVAILABLE
AddressDE

Party NameBoehringer Ingelheim International GmbH
Party Type10 - Original Applicant
Legal Entity Type27 - NOT AVAILABLE
AddressDE

Trademark Events


Event DateEvent Description
Tuesday, January 22, 2019APPLICATION FILING RECEIPT MAILED
Thursday, January 10, 2019SN ASSIGNED FOR SECT 66A APPL FROM IB
Wednesday, January 16, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, January 16, 2019ASSIGNED TO EXAMINER
Wednesday, January 23, 2019NON-FINAL ACTION WRITTEN
Thursday, January 24, 2019NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, February 6, 2019REFUSAL PROCESSED BY MPU
Wednesday, February 6, 2019NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, February 22, 2019REFUSAL PROCESSED BY IB
Thursday, March 7, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, March 8, 2019EXAMINERS AMENDMENT -WRITTEN
Friday, March 8, 2019EXAMINER'S AMENDMENT ENTERED
Friday, March 8, 2019EXAMINERS AMENDMENT MAILED
Wednesday, March 27, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 16, 2019PUBLISHED FOR OPPOSITION
Tuesday, April 16, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Thursday, March 7, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, March 7, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Saturday, March 9, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, April 19, 2019CORRECTION TRANSACTION RECEIVED FROM IB
Tuesday, July 2, 2019REGISTERED-PRINCIPAL REGISTER
Wednesday, October 2, 2019FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Wednesday, October 23, 2019GENERIC MADRID TRANSACTION CREATED
Wednesday, October 23, 2019GENERIC MADRID TRANSACTION SENT TO IB
Tuesday, July 2, 2024COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Sunday, December 1, 2019FINAL DECISION TRANSACTION PROCESSED BY IB
Monday, May 6, 2019CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED